2.3. Participants
malignancy, Small cell carcinoma, Neuroendocrine carcinoma
PANCREATIC CANCER, COLORECTAL CANCER, DISEASES
Patients with adjuvant/neoadjuvant or first-line palliative chemotherapy with regimen containing an intensively myleosuppressive agent on day 1 are enrolled.Enrollment criteria are: Patients with histologically confirmed malignancy who are scheduled for adjuvant/neoadjuvnat or first-line palliative chemotherapy with multi-day combination regimens. These regimens include mFOLFIRINOX for Pancreatic cancer, ECb and EP for Small cell carcinoma, Neuroendocrine carcinoma, and FOLFOX and FOLFIRI for colorectal cancer. Detailed contents of these regimen are described in Table Chemotherapy regimens.Combination therapies with atezolizumab are also included.Combination therapies with targeted agents such as cetuximab or bevacizumab are also included.The exclusion criteria are: Patients aged 76 years or older, Patients unable to receive 100% dose intensity in cycle 1; Patients who underwent radiation therapy within 1 month before starting treatment; Patient with other serious diseases or medical conditions; Pregnant or lactating women or those of childbearing age who do not consider contraception.